(R)-2-(4-ethoxyphenyl)-7-(3-fluoropyrrolidin-1-yl)-3,4-dimethyl-2H-pyrazolo[4,3-d]pyridazine

ID: ALA1801186

Chembl Id: CHEMBL1801186

PubChem CID: 56666408

Max Phase: Preclinical

Molecular Formula: C19H22FN5O

Molecular Weight: 355.42

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CCOc1ccc(-n2nc3c(N4CC[C@@H](F)C4)nnc(C)c3c2C)cc1

Standard InChI:  InChI=1S/C19H22FN5O/c1-4-26-16-7-5-15(6-8-16)25-13(3)17-12(2)21-22-19(18(17)23-25)24-10-9-14(20)11-24/h5-8,14H,4,9-11H2,1-3H3/t14-/m1/s1

Standard InChI Key:  YOXMEVDONXENBC-CQSZACIVSA-N

Associated Targets(Human)

CACNA2D1 Tclin Voltage-gated calcium channel alpha2/delta subunit 1 (266 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CACNA2D2 Tclin Voltage-gated calcium channel alpha2/delta subunit 2 (37 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Liver microsomes (8692 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 355.42Molecular Weight (Monoisotopic): 355.1808AlogP: 3.38#Rotatable Bonds: 4
Polar Surface Area: 56.07Molecular Species: NEUTRALHBA: 6HBD:
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 1.69CX LogP: 2.62CX LogD: 2.62
Aromatic Rings: 3Heavy Atoms: 26QED Weighted: 0.72Np Likeness Score: -1.86

References

1. Myatt JW, Healy MP, Bravi GS, Billinton A, Johnson CN, Matthews KL, Jandu KS, Meng W, Hersey A, Livermore DG, Douault CB, Witherington J, Bit RA, Rowedder JE, Brown JD, Clayton NM..  (2010)  Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic pain.,  20  (15): [PMID:20566291] [10.1016/j.bmcl.2010.05.026]

Source